Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 457

1.

The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma.

Wang DY, McQuade JL, Rai RR, Park JJ, Zhao S, Ye F, Beckermann KE, Rubinstein SM, Johnpulle R, Long GV, Carlino MS, Menzies AM, Davies MA, Johnson DB.

Oncologist. 2020 Mar;25(3):e602-e605. doi: 10.1634/theoncologist.2019-0518. Epub 2019 Nov 29.

2.

Neurologic complications of immune checkpoint inhibitors.

Haugh AM, Probasco JC, Johnson DB.

Expert Opin Drug Saf. 2020 Mar 11:1-10. doi: 10.1080/14740338.2020.1738382. [Epub ahead of print]

PMID:
32126176
3.

Acidophile Microbiology in Space and Time.

Johnson DB, Quatrini R.

Curr Issues Mol Biol. 2020 Feb 21;39:63-76. doi: 10.21775/cimb.039.063. [Epub ahead of print]

4.

Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors - a WHO pharmacovigilance database analysis.

Moey MYY, Gougis P, Goldschmidt V, Johnson DB, Lebrun-Vignes B, Moslehi J, Cadranel J, Salem JE.

Eur Respir J. 2020 Feb 20. pii: 2000038. doi: 10.1183/13993003.00038-2020. [Epub ahead of print] No abstract available.

PMID:
32079644
5.

Solid organ transplant rejection associated with immune-checkpoint inhibitors.

Saberianfar S, Nguyen LS, Manouchehri A, Lebrun-Vignes B, Moslehi JJ, Johnson DB, Hertig A, Salem JE.

Ann Oncol. 2020 Apr;31(4):543-544. doi: 10.1016/j.annonc.2020.01.012. Epub 2020 Jan 24. No abstract available.

PMID:
32061451
6.

Anterior Capsular Reconstruction Using a Dermal Allograft for an Irreparable Subscapularis Tear After Shoulder Arthroplasty: A Case Report.

Myers D, Triplet JJ, Johnson DB, Strakowski JA, Wiseman SP, Long NK.

JBJS Case Connect. 2020 Jan-Mar;10(1):e0468. doi: 10.2106/JBJS.CC.18.00468.

PMID:
32044774
7.

A tumor-intrinsic PD-L1-NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.

Theivanthiran B, Evans KS, DeVito NC, Plebanek MP, Sturdivant M, Wachsmuth LP, Salama AK, Kang Y, Hsu D, Balko JM, Johnson DB, Starr M, Nixon AB, Holtzhausen A, Hanks BA.

J Clin Invest. 2020 Feb 4. pii: 133055. doi: 10.1172/JCI133055. [Epub ahead of print]

8.

Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.

Nebhan CA, Johnson DB.

Expert Rev Anticancer Ther. 2020 Feb;20(2):137-145. doi: 10.1080/14737140.2020.1724539. Epub 2020 Feb 5.

PMID:
31997676
9.

Acidithiobacillus ferrianus sp. nov.: an ancestral extremely acidophilic and facultatively anaerobic chemolithoautotroph.

Norris PR, Falagán C, Moya-Beltrán A, Castro M, Quatrini R, Johnson DB.

Extremophiles. 2020 Mar;24(2):329-337. doi: 10.1007/s00792-020-01157-1. Epub 2020 Jan 24.

10.

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131).

Johnson DB, Zhao F, Noel M, Riely GJ, Mitchell EP, Wright JJ, Chen HX, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.

Clin Cancer Res. 2020 Jan 10. doi: 10.1158/1078-0432.CCR-19-3443. [Epub ahead of print]

PMID:
31924734
11.

Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.

Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB, Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL, Sise ME, Leaf DE.

J Am Soc Nephrol. 2020 Feb;31(2):435-446. doi: 10.1681/ASN.2019070676. Epub 2020 Jan 2.

PMID:
31896554
12.

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.

Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y.

J Clin Oncol. 2020 Feb 20;38(6):576-583. doi: 10.1200/JCO.19.01674. Epub 2019 Dec 4.

PMID:
31800340
13.

The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma.

Wang DY, McQuade JL, Rai RR, Park JJ, Zhao S, Ye F, Beckermann KE, Rubinstein SM, Johnpulle R, Long GV, Carlino MS, Menzies AM, Davies MA, Johnson DB.

Oncologist. 2019 Nov 29. pii: theoncologist.2019-0518. doi: 10.1634/theoncologist.2019-0518. [Epub ahead of print]

14.

Well-Leg Rhabdomyolysis After Prolonged Knee Arthroscopy: A Case Report.

Reynolds C, Johnson DB Jr, Triplet JJ, Comisar BR.

JBJS Case Connect. 2019 Dec;9(4):e0386. doi: 10.2106/JBJS.CC.18.00386.

PMID:
31770116
15.

Management of V600E and V600K BRAF-Mutant Melanoma.

Haugh AM, Johnson DB.

Curr Treat Options Oncol. 2019 Nov 18;20(11):81. doi: 10.1007/s11864-019-0680-z. Review.

PMID:
31741065
16.

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.

Das S, Johnson DB.

J Immunother Cancer. 2019 Nov 15;7(1):306. doi: 10.1186/s40425-019-0805-8. Review.

17.

Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors.

Vozy A, De Martin E, Johnson DB, Lebrun-Vignes B, Moslehi JJ, Salem JE.

Eur J Cancer. 2019 Dec;123:112-115. doi: 10.1016/j.ejca.2019.09.022. Epub 2019 Nov 1. No abstract available.

PMID:
31678768
18.

Enrichment and isolation of acid-tolerant sulfate-reducing microorganisms in the anoxic, acidic hot spring sediments from Copahue volcano, Argentina.

Willis G, Nancucheo I, Hedrich S, Giaveno A, Donati E, Johnson DB.

FEMS Microbiol Ecol. 2019 Dec 1;95(12). pii: fiz175. doi: 10.1093/femsec/fiz175.

PMID:
31665270
19.

Dissimilatory reduction of sulfate and zero-valent sulfur at low pH and its significance for bioremediation and metal recovery.

Johnson DB, Sánchez-Andrea I.

Adv Microb Physiol. 2019;75:205-231. doi: 10.1016/bs.ampbs.2019.07.002. Epub 2019 Oct 10.

PMID:
31655738
20.

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.

Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC.

J Clin Oncol. 2019 Nov 20;37(33):3142-3151. doi: 10.1200/JCO.19.00489. Epub 2019 Oct 3.

PMID:
31580757
21.

Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.

Wang LX, Quach HT, Moodabigil NV, Davis EJ, Sosman JA, Dusetzina SB, Johnson DB.

Cancer. 2020 Jan 15;126(2):322-328. doi: 10.1002/cncr.32542. Epub 2019 Oct 3.

PMID:
31580492
22.

Cardiovascular Toxicities Associated With Ibrutinib.

Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM, Moslehi JJ.

J Am Coll Cardiol. 2019 Oct 1;74(13):1667-1678. doi: 10.1016/j.jacc.2019.07.056.

PMID:
31558250
23.

Longer Survival With Anti-Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Association-In Reply.

Johnson DB, Ye F, Dewan AK.

JAMA Oncol. 2019 Sep 26. doi: 10.1001/jamaoncol.2019.3817. [Epub ahead of print] No abstract available.

PMID:
31556913
24.

Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?

Nordness MF, Hamel S, Godfrey CM, Shi C, Johnson DB, Goff LW, O'Dell H, Perri RE, Alexopoulos SP.

Am J Transplant. 2020 Mar;20(3):879-883. doi: 10.1111/ajt.15617. Epub 2019 Oct 28.

PMID:
31550417
25.

Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients.

Johnson DB, Taylor KB, Cohen JV, Ayoubi N, Haugh AM, Wang DY, Schlick BD, Voorhees AL, Gage KL, Fintelmann FJ, Sullivan RJ, Eroglu Z, Abramson RG.

Cancer Immunol Res. 2019 Nov;7(11):1755-1759. doi: 10.1158/2326-6066.CIR-18-0717. Epub 2019 Aug 28.

PMID:
31462410
26.

Pseudoaneurysm of the Pancreaticoduodenal Artery Associated with Duodenal Diverticulitis.

Hao SB, Johnson DB, Bonatti HJR.

Case Rep Surg. 2019 Jul 22;2019:2831234. doi: 10.1155/2019/2831234. eCollection 2019.

27.

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.

Vilgelm AE, Saleh N, Shattuck-Brandt R, Riemenschneider K, Slesur L, Chen SC, Johnson CA, Yang J, Blevins A, Yan C, Johnson DB, Al-Rohil RN, Halilovic E, Kauffmann RM, Kelley M, Ayers GD, Richmond A.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaav7171. doi: 10.1126/scitranslmed.aav7171.

PMID:
31413145
28.

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J.

Circulation. 2019 Jul 2;140(2):80-91.

PMID:
31390169
29.

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis.

Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem JM, Menzies AM, Tio M, Long GV, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger SM, Rushing EJ, Buchbinder EI, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM.

Nat Med. 2019 Aug;25(8):1243-1250. doi: 10.1038/s41591-019-0523-2. Epub 2019 Jul 22.

30.

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.

Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, Hoyt C, Pardoll DM, Danilova L, Taube JM.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1549. [Epub ahead of print]

PMID:
31318407
31.

Acidithiobacillus sulfuriphilus sp. nov.: an extremely acidophilic sulfur-oxidizing chemolithotroph isolated from a neutral pH environment.

Falagán C, Moya-Beltrán A, Castro M, Quatrini R, Johnson DB.

Int J Syst Evol Microbiol. 2019 Sep;69(9):2907-2913. doi: 10.1099/ijsem.0.003576.

PMID:
31274405
32.

Correlates of response and outcomes with talimogene laherperpvec.

Zhou AY, Wang DY, McKee S, Ye F, Wen CC, Wallace DE, Ancell KK, Conry RM, Johnson DB.

J Surg Oncol. 2019 Sep;120(3):558-564. doi: 10.1002/jso.25601. Epub 2019 Jul 2.

PMID:
31264725
33.

Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma.

Cann CG, Tillman BF, Davis EJ, Johnson DB.

Oncologist. 2019 Nov;24(11):1495-1496. doi: 10.1634/theoncologist.2019-0332. Epub 2019 Jun 18.

34.

Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.

Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M.

N Engl J Med. 2019 Jun 13;380(24):2377-2379. doi: 10.1056/NEJMc1901677. No abstract available.

PMID:
31189043
35.

Displaced Meniscus Tear in the Acute Postoperative Period After Total Hip Arthroplasty: A Case Report.

Johnson DB Jr, Triplet JJ, Streit AR, Long NK, Wasielewski RC.

JBJS Case Connect. 2019 Apr-Jun;9(2):e0124. doi: 10.2106/JBJS.CC.18.00124.

PMID:
31188794
36.

Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations.

Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sánchez V, Shyr Y, Sanders ME, Pietenpol JA.

Mol Cancer Res. 2019 Sep;17(9):1842-1853. doi: 10.1158/1541-7786.MCR-19-0257. Epub 2019 Jun 11.

37.

Upconversion of Cellulosic Waste Into a Potential "Drop in Fuel" via Novel Catalyst Generated Using Desulfovibrio desulfuricans and a Consortium of Acidophilic Sulfidogens.

Mikheenko IP, Gomez-Bolivar J, Merroun ML, Macaskie LE, Sharma S, Walker M, Hand RA, Grail BM, Johnson DB, Orozco RL.

Front Microbiol. 2019 May 10;10:970. doi: 10.3389/fmicb.2019.00970. eCollection 2019.

38.

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.

Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE.

J Immunother Cancer. 2019 May 22;7(1):134. doi: 10.1186/s40425-019-0617-x.

39.

Immunotherapy in Older Adults with Cancer.

Godby RC, Johnson DB, Williams GR.

Curr Oncol Rep. 2019 May 7;21(7):56. doi: 10.1007/s11912-019-0806-2. Review.

PMID:
31065907
40.

Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates.

Wang Y, Johnson DB, Lu S, Diaz LA Jr, Xu Y, Balko JM.

J Immunother Cancer. 2019 May 7;7(1):123. doi: 10.1186/s40425-019-0584-2.

41.

Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma.

Quach HT, Dewan AK, Davis EJ, Ancell KK, Fan R, Ye F, Johnson DB.

JAMA Oncol. 2019 Jun 1;5(6):906-908. doi: 10.1001/jamaoncol.2019.0046. No abstract available.

PMID:
30998826
42.

Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.

Guerrero E, Johnson DB, Bachelot A, Lebrun-Vignes B, Moslehi JJ, Salem JE.

Eur J Cancer. 2019 May;113:10-13. doi: 10.1016/j.ejca.2019.03.002. Epub 2019 Apr 4. No abstract available.

PMID:
30954881
43.

Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.

Quach HT, Robbins CJ, Balko JM, Chiu CY, Miller S, Wilson MR, Nelson GE, Johnson DB.

Oncologist. 2019 Jul;24(7):872-876. doi: 10.1634/theoncologist.2018-0722. Epub 2019 Apr 1.

44.

Adverse Events Associated With Immune Checkpoint Inhibitors-Reply.

Johnson DB, Chandra S, Sosman JA.

JAMA. 2019 Mar 26;321(12):1219-1220. doi: 10.1001/jama.2018.22123. No abstract available.

PMID:
30912830
45.

Mid-term outcomes following primary semi-constrained total knee arthroplasty in patients less than 60 years old, a retrospective review.

Johnson DB Jr, Triplet JJ, Gaines DR, Gupta A, Unverferth KL.

Knee. 2019 Jun;26(3):714-719. doi: 10.1016/j.knee.2019.02.001. Epub 2019 Mar 19.

PMID:
30902516
46.

Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma.

Davis EJ, Perez MC, Ayoubi N, Zhao S, Ye F, Wang DY, Sosman JA, Al-Rohil RN, Eroglu Z, Johnson DB.

J Immunother. 2019 Jul/Aug;42(6):221-227. doi: 10.1097/CJI.0000000000000258.

PMID:
30882548
47.

Validation of a Two-Item Food Security Screening Tool in a Dental Setting.

Radandt NE, Corbridge T, Johnson DB, Kim AS, Scott JM, Coldwell SE.

J Dent Child (Chic). 2018 Sep 15;85(3):114-119.

48.

Hematologic Complications of Immune Checkpoint Inhibitors.

Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB.

Oncologist. 2019 May;24(5):584-588. doi: 10.1634/theoncologist.2018-0574. Epub 2019 Feb 28.

49.

Retrograde Femoral Bone Graft Acquisition Using the Reamer-Irrigator-Aspirator.

Taylor BC, Triplet JJ, Johnson DB, Sharpe BD, Sullivan B, Canini C.

J Long Term Eff Med Implants. 2018;28(3):181-185. doi: 10.1615/JLongTermEffMedImplants.2018027914.

PMID:
30806274
50.

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.

Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE.

Am J Hematol. 2019 May;94(5):563-574. doi: 10.1002/ajh.25448. Epub 2019 Mar 13.

PMID:
30790338

Supplemental Content

Loading ...
Support Center